FOSPHENYTOIN SODIUM (fosphenytoin sodium) by Hikma is clinical pharmacology introduction following parenteral administration of fosphenytoin injection, fosphenytoin is converted to the anticonvulsant phenytoin. Approved for generalized tonic-clonic status epilepticus, prevention, treatment of seizures occurring during neurosurgery. First approved in 2008.
Drug data last refreshed 21h ago
CLINICAL PHARMACOLOGY Introduction Following parenteral administration of fosphenytoin injection, fosphenytoin is converted to the anticonvulsant phenytoin. For every mmol of fosphenytoin administered, one mmol of phenytoin is produced. The pharmacological and toxicological effects of fosphenytoin…
Worked on FOSPHENYTOIN SODIUM at Hikma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.